Sofinnova Ventures said Tuesday that Jennifer James was promoted to partner. James managed investor relations through Sofinnova’s most recent fundraising effort for SVP VIII, a $440M life science focused fund. James joined Sofinnova as VP of Marketing and Investor Relations in 2011.
MENLO PARK, Calif., July 24, 2013 /PRNewswire/ — Sofinnova Ventures, a Menlo Park investment firm, today announced the promotion of Jennifer James to Partner. James managed investor relations through the firm’s most recent fundraising effort for SVP VIII, a $440M life science focused fund. James’ promotion to Partner solidifies Sofinnova’s commitment to build best practices in communications and investor relations.
“Jennifer’s promotion to Partner both reflects her leadership informing and supporting Sofinnova’s limited partners and her excellent work on behalf of Sofinnova and its portfolio companies,” said Sofinnova General Partner, Michael Powell, Ph.D. “Sofinnova initially sought out Jennifer for her decade of experience in venture capital investor relations and marketing experience with healthcare companies. Today we mark the growth of that experience into expertise that sets a leading example among venture firms.”
Jennifer James joined Sofinnova as Vice President of Marketing and Investor Relations in 2011. James career in marketing and venture capital spans nearly two decades, including Director of Marketing and Communications for Alta Partners and Vice President at Blanc and Otus Public Relations, where she counseled venture capital and private equity firms, portfolio companies, investment banks, management consulting firms and law firms and venture backed philanthropy organizations.
James earned a Masters of Business Administration from the J.L. Kellogg Graduate School of Management at Northwestern University and a Bachelor of Arts in History from Bowdoin College.
About Sofinnova Ventures
Sofinnova Ventures has over 40 years of experience building healthcare companies into market leaders. With $1.4 billion in committed capital, the firm applies capital and expertise to take companies from inception to exit. Sofinnova closed its life science-focused $440M fund, SVP VIII, in late 2011. The firm’s investment team of M.Ds. and Ph.Ds. has significant scientific, operational and strategic experience, and specializes in financing later stage clinical products and growth companies. Our team partners with entrepreneurs to address patients’ unmet medical needs. Recent portfolio company exits and IPOs include SARcode, Preglem, Movetis, Vicept, NextWave, Hyperion (IPO), Intelllikine, and Durata (IPO). Sofinnova Ventures has offices in Menlo Park and La Jolla, California, and Dublin, Ireland. For more information, please visit www.sofinnova.com.